Article

Evaluating New-Generation Basal Insulin Therapy

https://www.pharmacytimes.org/landing/1137

https://www.pharmacytimes.org/landing/1137

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Christina Poh
Angel Qin, MD
Related Content
Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com
August 9th 2025

QRISK3 Tool Predicts Thrombotic Events in ET, PV

Jared Kaltwasser
AJMC podcast banner
August 9th 2025

What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD

Hayden E. Klein Skylar Jeremias Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Fetal Alcohol Syndrome | Image Credit: © GoodIdeas-stock.adobe.com
August 9th 2025

Understanding FAS: From Pregnancy Risks to Lifelong Care

Maggie L. Shaw
The Center for Biosimilars podcast banner
August 9th 2025

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

Skylar Jeremias Hillel P. Cohen, PhD Giuseppe Randazzo
Left bundle branch block may be an significant indicator of heart failure succeeding previous risk-factors like diabetes and hypertension. | Image Credit: AdobeStock_phonlamaiphoto.jpeg
August 9th 2025

Left Bundle Branch Block May Be Key Indicator of Progressive Heart Failure

Sabrina McCrear
Multiple sclerosis illustration | Image credit: Juan Gärtner - stock-adobe.com
August 9th 2025

Emerging MS Treatments Offer New Hope for Progressive Disease

Skylar Jeremias

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo